[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100377155":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":64,"collaborators":67,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":10,"maxAge":82,"enrollmentInfo":83,"targetDuration":86,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Cambridge University Hospitals NHS Foundation Trust","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Non-alcoholic fatty liver disease patients",null,"Children (\\\u003C18 years) with a diagnosis of NAFLD with radiological demonstration of increased liver fat and exclusion of other causes.",[13],{"name":14,"affiliation":15,"role":16},"David B Savage","University of Cambridge","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Jake P Mann, MRCPCH","CONTACT","0044124644","jm2032@cam.ac.uk",[24,36,53],{"facility":25,"status":26,"city":27,"state":10,"zip":10,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"Maastricht UMC","ACTIVE_NOT_RECRUITING","Maastricht","Netherlands","NL",{"type":31,"coordinates":32},"Point",[33,34],5.68889,50.84833,{"lat":34,"lon":33},{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"Addenbrooke's Hospital","RECRUITING","Cambridge","Cambridgeshire","CB2 0QQ","United Kingdom","UK",{"type":31,"coordinates":45},[46,47],0.11667,52.2,{"lat":47,"lon":46},[50],{"name":51,"role":20,"phone":52,"phoneExt":10,"email":22},"Jake P Mann","00447804124644",{"facility":54,"status":38,"city":55,"state":10,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Birmingham Children's Hospital","Birmingham",{"type":31,"coordinates":57},[58,59],-1.89983,52.48142,{"lat":59,"lon":58},[62],{"name":63,"role":20,"phone":10,"phoneExt":10,"email":10},"Indra van Mourik",{"type":16,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jake Mann","Hepatology registrar",[68,71],{"name":69,"class":70},"The European Association for the Study of the Liver","UNKNOWN",{"name":72,"class":70},"Children's Liver Disease Foundation","100377155","european-paediatric-non-alcoholic-fatty-liver-disease-registry-eu-pnafld-100377155",false,"NCT04190849","European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)","The European Paediatric Non-alcoholic Fatty Liver Disease Registry (EU-PNAFLD): a Prospective, Longitudinal Follow-up of Children With Non-alcoholic Fatty Liver Disease","EU-PNAFLD","Inclusion Criteria:\n\n* Diagnosis made under 18 years of age.\n* Diagnosis of NAFLD spectrum disease (simple steatosis (NAFL), steatosis with abnormal transaminases, NASH ± fibrosis or cirrhosis)\n* Diagnosis established by:\n\n  * Radiological evidence of hepatic steatosis (e.g. increased hepatic echogenicity on ultrasound), with\n  * Exclusion of secondary causes (negative serological liver screen for HBV\u002FHCV, caeruloplasmin \\>0.20g\u002FL, no history of excess alcohol consumption, no evidence of iron overload, and no clinically significant alpha-1 antitrypsin (A1AT) phenotype (i.e. SZ, ZZ, SS), with or without\n  * Histology (\\>5% steatosis and histology consistent with paediatric NAFLD)\n\nExclusion Criteria:\n\n* Secondary fatty liver disease (e.g. glycogen storage diseases, Wilson disease, viral hepatitis, drug-related, autoimmune hepatitis, type 1 diabetes mellitus)\n* Post-transplant fatty liver\n* \\>20g\u002Fday ethanol intake","ALL","18 Years",{"count":84,"type":85},2000,"ESTIMATED","30 Years","OBSERVATIONAL","The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by relevant international specialists. This collaboration will build on existing infrastructure (local databases and bio-repositories) and will align with the adult European NAFLD Registry (\"EPoS\", Elucidating Pathways of Steatohepatitis study) to allow long-term follow-up supported by translational studies. Through an international, well-characterised large-scale cohort, we hope to: facilitate multi-centre clinical trials; extend our understanding of the key disease mechanisms of NAFLD; and establish the natural history of paediatric NAFLD.",[90,91,92],"Non-Alcoholic Fatty Liver Disease","Non-alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[94,95,96,97,98],"Cirrhosis","Liver disease","Hepatocellular carcinoma","Type 2 diabetes","Atherosclerosis","2022-02-17",{"date":101,"type":102},"2022-03-04","ACTUAL",{"date":104,"type":102},"2017-11-14",{"date":106,"type":85},"2047-11",{"name":5,"class":6},3]